医学
系统回顾
梅德林
检查表
科克伦图书馆
荟萃分析
协议(科学)
随机对照试验
循证医学
分级(工程)
重症监护医学
外科
替代医学
内科学
病理
心理学
土木工程
政治学
法学
认知心理学
工程类
作者
Xinyu Zhang,Kelu Yang,Yang Li,Rui-Shu Li,Shi-Qi Wang,Xiaonan Liu,Quan Wang
出处
期刊:BMJ Open
[BMJ]
日期:2023-12-01
卷期号:13 (12): e077279-e077279
被引量:1
标识
DOI:10.1136/bmjopen-2023-077279
摘要
Introduction Rectal cancer is one of the top 10 cancers worldwide. Up to 80% of patients with rectal tumours have had sphincter-saving surgery, mainly due to the large expectation of anal preservation. However, patients tend to experience low anterior resection syndrome (LARS) after rectal resection, which is disordered bowel function that includes faecal incontinence, urgency, frequent defecation, constipation and evacuation difficulties. LARS, with an estimated prevalence of 41%, has been reported to substantially decrease the quality of life of patients. However, no comprehensive preventive strategies are currently available for LARS. This systematic review aims to synthesise evidence on the current LARS preventive strategies. Methods and analysis This protocol is reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) checklist. Literature in PubMed (via Medline), Embase and the Cochrane Library from inception to July 2023 will be searched to identify articles relevant to preventive effectiveness against LARS. The Cochrane Collaboration’s risk of bias tool for randomised controlled trials and the Newcastle-Ottawa Scale for clinical controlled trials, cohort studies and case–control studies will be used to assess the risk of bias. We will group the included studies by the type of LARS prevention strategy and present an overview of the main findings in the form of evidence mapping. A meta-analysis is planned if there is no substantial clinical heterogeneity between the included studies. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) will be used to evaluate the quality of the evidence. Ethics and dissemination Ethical approval is not needed for systematic review of published data. The findings will be published in a peer-reviewed journal and disseminated at scientific conferences. PROSPERO registration number CRD42023402886.
科研通智能强力驱动
Strongly Powered by AbleSci AI